The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I did wonder some time back if a JV with ASLR would be the outcome, but if it goes as per the RNS, that works! gla.
Still some uncertainty, but if this does go through, I think the BOD should get a big thumbs up here, it would be a great outcome for all of the LTAs.
Wow....some RNS!!! I did not think anything like that as a possible outcome. Obviously ASLR will have a part to play, and I think as they wanted a piece of the pie after buying in after MESH, that is a good offer?
If this does come to fruition, it could well have been worth the wait. GLA.
Asimilar Group plc
('Asimilar' or the 'Company')
Update on proposed transaction with Sentiance
Further to the announcements on 4 and 12 March 2020, Asimilar Group plc (AIM: ASLR) is working on preparing an admission document relating to the proposed subscription in and the granting of options over the equity of Sentiance N.V. ('Sentiance').
The Company notes the announcement published by Mesh Holdings plc ('Mesh') this morning that Mesh has made an offer to acquire the entire issued share capital of Sentiance.
As part of this offer, the Company has received a proposal from Mesh that Asimilar would receive compensation from Mesh in the form of new ordinary shares in Mesh in consideration for the Company novating the following to Mesh:
i) its rights to subscribe for 10,000 new Sentiance shares at a price of €750 per share ("Initial Investment");
ii) an option to purchase 32,225 existing Sentiance shares at an exercise price of €650 per share ("Option 1"); and
iii) a further option to subscribe for 10,000 new Sentiance shares at an exercise price of €750 per share ("Option 2"), all as announced by Asimilar on 4 March 2020.
The Board of Asimilar is exploring the terms of this proposal with Mesh and is pursuing appropriate due diligence to assess its merits.
In the meantime, Asimilar is continuing to work with its Nominated Adviser and other professional advisers on its admission document in relation to the proposals announced on 4 and 12 March 2020.
Further announcements will be made in due course.